Advances in nanomaterials for the diagnosis and treatment of ischemic heart disease

TL;DR

This paper reviews how nanomaterials are being developed for diagnosing and treating ischemic heart disease, highlighting progress and challenges in clinical translation.

Contribution

A comprehensive review of nanomaterial applications in ischemic heart disease, emphasizing recent advances and barriers to clinical adoption.

Findings

Nanomaterials offer precise diagnosis and treatment through control at the nanoscale.

China and the USA lead in research on nanotechnology for ischemic cardiomyopathy.

Few nanomedicine products have reached clinical approval despite preclinical success.

Abstract

Ischemic heart disease (IHD) remains a leading cause of mortality worldwide. Despite timely reperfusion therapy, myocardial ischemia can still lead to ventricular remodeling, arrhythmia, and heart failure, contributing to the high prevalence of cardiovascular disease. Nanomaterials provides innovative technical methods and tools for precise clinical diagnosis and effective treatment through nanoscale control of materials and biological interactions. In this study, bibliometrics have been harnessed to explore the region and topic distribution characteristics of nanotechnology in the field of ischemic cardiomyopathy. The key directions in this field contain cardiac tissue engineering, biosensor, targeted drug delivery and molecular imaging. China and USA are the leading contributors in this filed. Recent literature demonstrates rapid growth in nanomaterial-based strategies and their broad application in preclinical models of IHD. However, only a limited number of nanomedicine products have progressed to clinical approval. This review summarizes the current advances in nanotechnology for IHD, highlights remaining challenges, and discusses future directions to facilitate clinical translation.

Figures